Mid-Western Cancer Centre, Limerick, Ireland
Keith Ian Quintyne , Bernie Woulfe , Linda Coate , Rajnish K. Gupta
Background: Obesity or body mass index (BMI) > 30kg/m2 is a grave public health concern. Poorer outcome has been documented in obese breast cancer patients. We report the use of the Oncotype Dx Recurrence Score (RS) assay and its correlation with BMI and pathologic data. Methods: Study period: 01/09/08 – 31/05/12. Data was derived from: MWCC database; pathology reports; patient files; RS reports. Statistical analysis was carried out using R. Results: 89 patients were found. Median follow-up: 21.4 months. See Table for data. Conclusions: For this cohort: A skewed pattern in RS assay scores was observed in obese patients, where there were more intermediate and high scores, although this was not significant in multivariate model; tumour size and grade were shown to correlate with the RS assay results; these findings are thought-provoking and certainly can augment to the accruing energy balance data that has been increasingly of interest in oncological research.
No. | Range | Median | RS |
Significance |
|||||
---|---|---|---|---|---|---|---|---|---|
Low | Intermediate | High | Unknown | Univariate | Multivariate | ||||
RS Assay U/k |
89 2 |
0–44 | 17 | 45 (51%) | 36 (40%) | 6 (7%) | |||
Age (y) ≤ 44 45 – 54 55 – 64 ≥ 65 |
89 10 31 24 24 |
30.6–72.3 | 55.2 | 7 (70%) 16 (52%) 11 (46%) 11 (46%) |
2 (20%) 12 (39%) 12 (50%) 10 (42%) |
1 (10%) 1 (3%) 1 (4%) 3 (13%) |
0 (0%) 2 (6%) 0 (0%) 0 (0%) |
0.46 | 0.71 |
Size (cm) ≤ 1.00 1.01 – 2.00 ≥ 2.01 |
89 8 54 27 |
0.8–5.0 | 1.7 | 3 (38%) 29 (54%) 13 (48%) |
3 (38%) 23 (43%) 10 (37%) |
1 (13%) 1 (2%) 4 (15%) |
1 (13%) 1 (2%) 0 (0%) |
0.02 | 0.06 |
Histology Ductal Lobular Mixed |
89 72 16 1 |
38 (53%) 7 (44%) 0 (0%) |
28 (39%) 7 (44%) 1 (100%) |
5 (7%) 1 (6%) 0 (0%) |
1 (1%)1 (6%) 0 (0%) |
0.85 | 0.86 | ||
Grade I II III |
89 8 74 7 |
1 (13%) 42 (57%) 2 (29%) |
7 (88%) 26 (35%) 3 (43%) |
0 (0%) 4 (5%) 2 (29%) |
0 (0%) 2 (3%) 0 (0%) |
0.04 | 0.04 | ||
PgR +ve – ve |
89 78 11 |
43 (55%) 2 (18%) |
29 (37%) 7 (64%) |
5 (6%) 1 (9%) |
1 (1%) 1 (9%) |
0.11 | 0.09 | ||
Menopause Pre Post U/k |
89 31 57 1 |
20 (65%) 25 (44%) 0 (0%) |
7 (23%) 28 (49%) 1 (100%) |
2 (6%) 4 (7%) 0 (0%) |
2 (6%) 0 (0%) 0 (0%) |
0.56 | 0.81 | ||
Weight (kg) |
89 | 51–106 | 71.0 | 0.29 | |||||
BMI (kg/m2) ≤ 25 25.1 – 30 ≥ 30.1 U/k |
89 31 31 24 3 |
20.0–44.1 | 27.2 | 19 (61%) 16 (52%) 9 (38%) 1 (33%) |
8 (26%) 13 (42%) 13 (54%) 2 (67%) |
3 (10%) 1 (3%) 2 (8%) 0 (0%) |
1 (3%) 1 (3%) 0 (0%) 0 (0%) |
0.02 | 0.13 |
* Unknown: U/k, PgR: progesterone receptor, +ve: positive, -ve: negative; % have been rounded and might not total 100%.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Annual Meeting
First Author: Grace B Gallagher
2022 ASCO Annual Meeting
First Author: Georg Pfeiler
2021 ASCO Annual Meeting
First Author: Tarah Jean Ballinger
2023 ASCO Annual Meeting
First Author: Po-Hua Chen